Individualizing Therapy in Low-Risk MDS: New Evidence and Options for Your Patients

Gain expert insights on the latest advancements in managing low-risk myelodysplastic syndromes through an on-demand webcast of a roundtable discussion and a commentary addressing audience questions from a live webinar.

Share

Program Content

Activities

Managing LR MDS
Individualizing Therapy in Low-Risk MDS: New Evidence and Options for Your Patients
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 31, 2024

Expires: May 30, 2025

Activities

Myelodysplastic Syndromes at ASCO 2024
Individualizing Therapy in Low-Risk MDS: New Evidence and Options for Your Patients
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2024

Expires: December 13, 2024

Activities

FAQs on LR-MDS
Experts Answer Key Questions on Managing Anemia in Patients With Lower-Risk MDS
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 08, 2024

Expires: July 07, 2025

Faculty

cover img faculity

Rami Komrokji, MD

Section Head – Leukemia & MDS, Vice Chair
Department of Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

cover img faculity

Maximilian Stahl, MD

Department of Medical Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

cover img faculity

Amer Zeidan, MBBS, MHS

Associate Professor of Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb